The Effect of Mesenchymal Stem Cells Transplantation on Cardiac Functioning and Contractility in Experimental Myocardial Infarction

  • S. I. Estrin State Institution “V. T. Zaitsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine; State Institution “V. K. Gusak Institute of Urgent and Reconstructive Surgery of National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
  • T. V. Kravchenko State Institution “V. T. Zaitsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • A. O. Kovalchuk State Institution “V. T. Zaitsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
Keywords: cardiomyoplasty, mesenchymal stem cells, myocardial infarction, cardiac contractility


Introduction. Heart failure as a result of ischemic myocardial remodeling is one of the most severe diseases with poor prognosis. Drug therapy alone with surgical or percutaneous revascularization of damaged myocardium often fails to achieve optimum effect in the treatment of the mentioned syndrome. Cell cardiomyoplasty using autologous bone marrow derived mesenchymal stem cells (BM-MSCs) has already proved to be promising alternative to both these treatment methods, as it’s aimed directly at restoration of normally functioning myocard.

The aim. To study the effects of different techniques of cardiomyoplasty with BM-MSCs on morphometrical and functional indices of post-infarctional left ventricular remodeling in experiment.

Materials and methods. An experimental model of myocardial infarction in laboratory rats was used for the research. The survived animals were equally divided into 5 groups; the animals of 3 groups underwent BM-MSC transplantation. A certain technique of cardiomyoplasty was used in each of the 3 groups: direct injection into necrotic myocardium, intravenous injection and injection inside left ventricular cavity (which imitates intracoronalintroduction). Other 2 groups were comparison groups where the animals did not achieve BM-MSCs after infarction. There was also control group with intact animals with normal values of all the studied indices. The following invasive and noninvasive measurements of functional heart indices have been done in all research groups: left ventricular weight and its relation to body weight, end-systolic and end-diastolic left ventricular internal dimensions, fractional shortening, ejection fraction, stroke volume, heart rate, systemic arterial pressure and left ventricular inner pressure, both systolic and diastolic. The follow-up period was 1 and 3 months after the experiment. Finally, all animals were euthanized and autopsied, and the results of macroscopic examination of their hearts have been matched with aforecited functional indices in each group.

Results and discussion. The analysis of all measured parameters and their comparison between groups have revealed that BM-MSC transplantation (irrespective of technique) conduces to reliably significant retention of functioning myocardium volume, reliably significant improvement of contractility parameters, particularly, reduced end-systolic and end-diastolic internal dimensions, increased ejection fraction, fractional shortening and stroke volume; it also contributes to maximal inalterability of such hemodynamic parameters as heart rate, systemic arterial pressure, left ventricular inner pressure. In addition, in all 3 groups of cell therapy the indices of contractility and pump function of the left ventricle were very close to normal rates. But the optimal results have been obtained in the group of direct intramyocardial injections.

Conclusion. Cell cardiomyoplasty with BM-MSCs tends to prevent ischemic myocardial remodeling and, as a result, to improve myocardial contractility and neutralize manifestations of severe heart failure in short-term follow-up of 1 and 3 months.


  1. Voronkov LG, Berezin OE, Zharinova VYu, Zhebel VM, Koval OA, Rudik YuS, et al. [Biological markers and their use in heart failure. Consensus of Ukrainian Association of Cardiology, Ukrainian Heart Failure Association and Ukrainian Association on Acute Cardiovascular Care]. Ukrainian Journal of Cardiology. 2019;26(2):11-22. Ukrainian.
  2. Nikonenko AS, Molodan AV, Ivashchuk VA. [Evaluation of the deformation properties of the myocardium in patients with ischemic heart disease with marked dilatation of the left ventricular cavity is complicated by heart failure]. Cardiovascular Surgery Herald. 2015;23:135-139. Ukrainian.
  3. Gabriyelyan AV, Smorzhevskiy VY, Onishchenko VF, Lukach PM, Beleyovich VV, Domanskiy TM. Koronarne shuntuvannia u khvorykh na ishemichnu khvorobu sertsia z khronichnoiu sertsevoiu nedostatnistiu [Coronar bypass grafting in patients with ischemic heart disease complicated by heart failure]. Sertsevo-sudynna khirurhiia: shchorichnyk naukovykh prats Assotsiatsii sertsevo-sudynnykh khirurhiv Ukrainy. 2009;17:103-107. Ukrainian.
  4. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1(1):4-25.
  5. Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018;104(3):230-236.
  6. Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in patients with heart failure with preserved ejection fraction. Clin Med Insights Cardiol. 2018;12:1179546817751609.
  7. Krykunov OA, Rudenko KV, Rusnak AO, Luchynets OF, Buriak RV, Shapovalova VV. [A complex approach to the treatment in patients with dilated cardiomyopathy]. Cardiovascular Surgery Herald. 2015;23:77-82. Ukrainian.
  8. Blair A. The Use of Left Ventricular Assist Devices in End-Stage Heart Failure. Crit Care Nurs Q. 2018;41(4):376-382.
  9. Nishimura S, Izumi C, Himura Y, Kuroda M, Amano M, Harita T, et al. Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of 123 I-metaiodobenzylguanidine scintigraphy. Heart Vessels. 2019 Feb;34(2):259-267.
  10. Kanda P, Davis D. Cellular mechanisms underlying cardiac engraftment of stem cells. Expert Opinion on Biological Therapy. 2017 Sep;17(9):1127-1143.
  11. Gabriyelyan AV, Smorzhevskiy VY, Domanskiy TM, Onishchenko VF. [Sourses of stem cells for the treatment of myocardial contractility disorders]. Heart and Vessels. 2011;3(35):89-92. Ukrainian.
  12. Gabriyelyan AV, Smorzhevskiy VY, Onishchenko VF, Garasymov DY, Topchuk YI, Myronyuk OI, et al. Aktualni problemy sertsevo-sudynnoi khirurhii [Actual problems of cardiovascular surgery]. Suchasni problem aterosklerosu – vid gipotez do faktiv: Proceedings of the VII South Ukrainian Scientific and Practical Conference; 2012 Apr 11; Odesa, Ukraine. Odesa; 2012. p. 146. Ukrainian.
  13. Gabriyelyan AV, Salutin RV, Yakushev AV, Onishchenko VF, Shabliy VM, Domanskiy TM, et al. [Contemporary approaches and methods of stem cell transplantation in patients with end-stage heart failure]. Cardiac Surgery and Interventional Cardiology. 2014;1(6):8-12. Ukrainian.
  14. Gabriyelyan AV. Sovremenniye metody khirurgicheskogo lecheniya refrakternoy serdechnoy nedostatochnosti pri ishemicheskoy bolezni serdtsa [Contemporary techniques in the surgical treatment of refractory post-ischemic heart failure]. Klinicheskaia khirurgiia. 2014;1,2:52-55. Russian.
  15. Dzholdasbekova A, Fedotovskikh G, Askarov M, Komsabakova B, Baigenzhina A, Kairatova A, et al. [Systemic administration of autologous mononuclear precultured bone marrow stem cells in heart failure]. Clinical Medicine of Kazakhstan. 2015;3(37):14-18. Russian.
How to Cite
Estrin, S. I., Kravchenko, T. V., & Kovalchuk, A. O. (2021). The Effect of Mesenchymal Stem Cells Transplantation on Cardiac Functioning and Contractility in Experimental Myocardial Infarction. Ukrainian Journal of Cardiovascular Surgery, (1 (42), 28-37.